ClinicalTrials.gg
TerminatedNCT07267130Updated Aug 27, 2026

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects

A Phase 1 interventional study of TQC3302 inhalation spray and TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation in Chronic Obstructive Pulmonary Disease, sponsored by Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

Why this study was terminated
This study shall be terminated as a result of strategic adjustments to the company-sponsored research and development of TQC3302 Inhalation Spray.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited — 2 open to participants now, 6 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sino Biopharmaceutical Limited.

Enrollment
17th of 17
33 · median 113
Started
2025
with 4 others
Phase 1
7 of 17
none open now
Registered
15th of 17
by date

Among the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, this one is the 17th largest by enrollment, is one of 5 that started in 2025, is one of 7 in phase 1, and was the 15th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pulmonary Disease, Chronic Obstructive by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

Groups 1, 3, 4, 5 and 6 of this research team adopted a single-center, open-label design. Group 2 used a three-sequence, three-period crossover design, where participants in this dose group were randomly assigned to the three sequences in a 1:1:1 ratio to undergo three-period crossover administration. Healthy adult subjects were selected to use TQC3302 inhalation spray to evaluate the safety, tolerability, and pharmacokinetic characteristics of single and multiple inhalations of TQC3302 inhalation spray in healthy participants.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily joined the study, sign form before the study and fully understand the study content
  • Healthy subjects aged between 18 and 55 years (inclusive),both male and female
  • The male subject should weigh at least 50kg, the female subject should weigh at least 45kg. And (BMI) within 19\~28 kg/m2
  • Inhalation administration training qualified.
  • During the screening period, the percentage of predicted value for (FEV1) before bronchodilator administration is ≥80%, and FEV1/forced vital capacity (FVC) is ≥70%.
  • Have no pregnancy plan and voluntarily take effective measures from time of screening to at least 90 days after the last dose (subjects and their partners)

Exclusion criteria

Exclusion Criteria:

  • Individuals with a history of glaucoma, functional constipation, benign prostatic hyperplasia, urinary tract obstruction, etc
  • Current history of active tuberculosis, bronchiectasis or other non-specific lung diseases
  • People who have received or are planning to receive inactive or active vaccines during the 30 days prior to the screening period and the entire study period
  • Any history of drug allergies, Individuals with a specific history of allergies or allergies
  • Had undergone surgery within 1 month prior to screening period or expected to undergo surgery during the study period
  • People with special dietary requirements who cannot follow a standard diet;
  • People who have potential difficulty in blood collection, or have a history of halo needles or blood sickness;
  • History of drug or narcotics abuse or a positive result of urine drug test at screening
  • People who have abnormal and results in vital signs, physical examination, laboratory tests, Chest radiograph and abdominal ultrasound during screening period
  • Subjects Positive for Any of Virus Surface Antigen (HBsAg), Virus Antibody (Anti-HCV), Antibody (Anti-HIV), and Treponema Pallidum Antibody (Anti-TP)
  • Pregnant or lactating women or those with positive blood pregnancy test results during the screening period
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    TQC3302 inhalation spray (50/2.5/2.5μg)

    Administered as a single dose

    Drug: TQC3302 inhalation spray

  • Experimental
    TQC3302/Spiolto® Respimat® /Pulmicort®

    Each drug is administered as a single dose. TQC3302 inhalation spray (200/2.5/2.5μg); Spiolto® Respimat® : Tiotropium bromide and olodaterol hydrochloride inhalation spray (2.5/2.5μg); Pulmicort® : Budesonide Powder for Inhalation (200μg)

    Drug: TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation

  • Experimental
    Pulmicort®/Spiolto® Respimat®

    Each drug is administered as a single dose. Spiolto® Respimat®: Tiotropium bromide and olodaterol hydrochloride inhalation spray (2.5/2.5μg) ; Pulmicort®: Budesonide Powder for Inhalation (200μg) TQC3302 inhalation spray (200/2.5/2.5μg)

    Drug: Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray

  • Experimental
    Spiolto® Respimat® /Pulmicort®/TQC3302

    Each drug is administered as a single dose. Pulmicort®: Budesonide Powder for Inhalation (200μg); TQC3302 inhalation spray (200/2.5/2.5μg); Spiolto® Respimat®: Tiotropium bromide and olodaterol hydrochloride inhalation spray (2.5/2.5μg)

    Drug: Budesonide Powder for Inhalation+ TQC3302 inhalation spray+ Tiotropium bromide and olodaterol hydrochloride inhalation spray

  • Experimental
    TQC3302 inhalation spray (200/5/5μg)-single dose

    TQC3302 inhalation spray is administered as a single dose.

    Drug: TQC3302 inhalation spray

  • Experimental
    TQC3302 inhalation spray (400/5/5μg)

    TQC3302 inhalation spray is administered as a single dose

    Drug: TQC3302 inhalation spray

  • Experimental
    TQC3302 inhalation spray (200/5/5μg)

    Single dose during Day 1-Day 7

    Drug: TQC3302 inhalation spray

  • Experimental
    TQC3302 inhalation spray (400/5/5μg)-single dose

    single dose during Day 1-Day 7

    Drug: TQC3302 inhalation spray

  • Experimental
    TQC3302 inhalation spray (400/5/5μg) -two dose

    Two dose during Day 1-Day 7

    Drug: TQC3302 inhalation spray

Interventions

  • DrugTQC3302 inhalation spray

    TQC3302 inhalation spray is a targeted inhibitor

  • DrugTQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation

    TQC3302 inhalation spray is a targeted inhibitor, Tiotropium bromide and olodaterol hydrochloride inhalation spray is a targeted inhibitor, Budesonide Powder for Inhalation is a Inhaled Corticosteroids.

  • DrugTiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray

    TQC3302 inhalation spray is a targeted inhibitor, Tiotropium bromide and olodaterol hydrochloride inhalation spray is a targeted inhibitor, Budesonide Powder for Inhalation is a Inhaled Corticosteroids.

  • DrugBudesonide Powder for Inhalation+ TQC3302 inhalation spray+ Tiotropium bromide and olodaterol hydrochloride inhalation spray

    TQC3302 inhalation spray is a targeted inhibitor, Tiotropium bromide and olodaterol hydrochloride inhalation spray is a targeted inhibitor, Budesonide Powder for Inhalation is a Inhaled Corticosteroids.

  • DrugTQC3302 inhalation spray

    TQC3302 inhalation spray is a targeted inhibitor

06

What researchers measure

Primary outcomes

  1. Treatment Emergent Adverse Event

    The incidence and severity of adverse events after treatment From the use of the investigational drug until the last study visit.

    Time frame: From the use of the investigational drug until the last study visit, up to Day 14

  2. The subject with abnormal security check

    The frequency, incidence, and severity of laboratory tests, vital signs, physical examinations, electrocardiogram examinations, etc.

    Time frame: From the use of the investigational drug until the last study visit, up to Day 14

Secondary outcomes

  1. Cmax after dose

    The Cmax is the maximum observed plasma concentration of study drug

    Time frame: Single dose:pre-dose, at 2,5,8,12,25,45 minutes,1,2,4,8,12,24, 48,72,120 hours after-dose (When using Budesonide Powder for Inhalation, there is no need to monitor at 48, 72, and 120 hours after the end of administration)

  2. Area Under the Concentration-Time Curve From 0 to Last Observation (AUC [0-t])

    To characterize the pharmacokinetics of TQC3302 by assessment of area under the plasma concentration time curve from the first dose to a certain time point

    Time frame: Single dose:pre-dose, at 2,5,8,12,25,45 minutes,1,2,4,8,12,24, 48,72,120 hours after-dose (When using Budesonide Powder for Inhalation, there is no need to monitor at 48, 72, and 120 hours after the end of administration)

  3. Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity])

    To characterize the pharmacokinetics of TQC3302 by assessment of area under the plasma concentration time curve from 0 extrapolated to infinity.

    Time frame: Single dose:pre-dose, at 2,5,8,12,25,45 minutes,1,2,4,8,12,24, 48,72,120 hours after-dose (When using Budesonide Powder for Inhalation, there is no need to monitor at 48, 72, and 120 hours after the end of administration)

  4. Time to reach maximum (peak) plasma concentration following drug administration (Tmax)

    To characterize the pharmacokinetics of TQC3302 by assessment of time to reach maximum plasma concentration after single dosing.

    Time frame: Single dose:pre-dose, at 2,5,8,12,25,45 minutes,1,2,4,8,12,24, 48,72,120 hours after-dose (When using Budesonide Powder for Inhalation, there is no need to monitor at 48, 72, and 120 hours after the end of administration)

  5. Half-life (t1/2)

    Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

    Time frame: Single dose:pre-dose, at 2,5,8,12,25,45 minutes,1,2,4,8,12,24, 48,72,120 hours after-dose (When using Budesonide Powder for Inhalation, there is no need to monitor at 48, 72, and 120 hours after the end of administration)

  6. Apparent volume of distribution (Vd/F)

    Apparent volume of distribution of the TQC3302 in plasma.

    Time frame: Single dose:pre-dose, at 2,5,8,12,25,45 minutes,1,2,4,8,12,24, 48,72,120 hours after-dose (When using Budesonide Powder for Inhalation, there is no need to monitor at 48, 72, and 120 hours after the end of administration)

  7. Apparent clearance (CL/F)

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the body.

    Time frame: Single dose:pre-dose, at 2,5,8,12,25,45 minutes,1,2,4,8,12,24, 48,72,120 hours after-dose (When using Budesonide Powder for Inhalation, there is no need to monitor at 48, 72, and 120 hours after the end of administration)

  8. Peak concentration (Cmax) after the first administration

    The Cmax is the maximum observed plasma concentration of study drug.

    Time frame: Multiple dosing: at 2, 5, 8, 12, 25, 45 minutes, 1, 2, 4, 8, 12 hours after the first administration

  9. Time to reach maximum (peak) plasma concentration after the first administration (Tmax)

    To characterize the pharmacokinetics of TQC3302 by assessment of time to reach maximum plasma concentration after the first administration.

    Time frame: Multiple dosing: at 2, 5, 8, 12, 25, 45 minutes, 1, 2, 4, 8, 12 hours after the first administration

  10. Half-life after the first administration

    Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

    Time frame: Multiple dosing: at 2, 5, 8, 12, 25, 45 minutes, 1, 2, 4, 8, 12 hours after the first administration

  11. Area Under the Concentration-Time Curve From 0 to Last Observation after the first administration

    To characterize the pharmacokinetics of TQC3302 by assessment of area under the plasma concentration time curve from the first dose to a certain time point.

    Time frame: Multiple dosing: at 2, 5, 8, 12, 25, 45 minutes, 1, 2, 4, 8, 12 hours after the first administration

  12. Area Under the Concentration-Time Curve From Zero to Infinity after the first administration

    To characterize the pharmacokinetics of TQC3302 by assessment of area under the plasma concentration time curve from 0 extrapolated to infinity

    Time frame: Multiple dosing: at 2, 5, 8, 12, 25, 45 minutes, 1, 2, 4, 8, 12 hours after the first administration

  13. Peak concentration (Cmax)

    The Cmax is the maximum observed plasma concentration of study drug

    Time frame: Multiple dosing: at 2, 5, 8, 12, 25, 45 minutes, 1, 2, 4, 8, 12, 24 hours after the first dose, before Day 5, 6, 7, at 2, 5, 8,1 2, 25, 45 minutes, 1, 2 , 4, 8, 12, 24, 48, 72, 120 hours after Day 7 dose

  14. Time to reach maximum (peak) plasma concentration following drug administration

    To characterize the pharmacokinetics of TQC3302 by assessment of time to reach maximum plasma concentration after multiple dosing

    Time frame: Multiple dosing: at 2, 5, 8, 12, 25, 45 minutes, 1, 2, 4, 8, 12, 24 hours after the first dose, before Day 5, 6, 7, at 2, 5, 8,1 2, 25, 45 minutes, 1, 2 , 4, 8, 12, 24, 48, 72, 120 hours after Day 7 dose

  15. Area Under the Concentration-Time Curve From 0 to Last Observation (AUC [0-t])

    To characterize the pharmacokinetics of TQC3302 by assessment of area under the plasma concentration time curve from the first dose to a certain time point

    Time frame: Multiple dosing: at 2, 5, 8, 12, 25, 45 minutes, 1, 2, 4, 8, 12, 24 hours after the first dose, before Day 5, 6, 7, at 2, 5, 8,1 2, 25, 45 minutes, 1, 2 , 4, 8, 12, 24, 48, 72, 120 hours after Day 7 dose

  16. Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity])

    To characterize the pharmacokinetics of TQC3302 by assessment of area under the plasma concentration time curve from 0 extrapolated to infinity.

    Time frame: Multiple dosing: at 2, 5, 8, 12, 25, 45 minutes, 1, 2, 4, 8, 12, 24 hours after the first dose, before Day 5, 6, 7, at 2, 5, 8,1 2, 25, 45 minutes, 1, 2 , 4, 8, 12, 24, 48, 72, 120 hours after Day 7 dose

  17. Area Under the Concentration-Time Profile From Time Zero to the Dosing Interval Tau

    Area Under the Concentration-Time Profile From Time Zero to the Dosing Interval Tau (AUCtau) of TQC3302 from the first dose to a certain time point.

    Time frame: Multiple dosing: at 2, 5, 8, 12, 25, 45 minutes, 1, 2, 4, 8, 12, 24 hours after the first dose, before Day 5, 6, 7, at 2, 5, 8,1 2, 25, 45 minutes, 1, 2 , 4, 8, 12, 24, 48, 72, 120 hours after Day 7 dose

  18. Half-life (t1/2): Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma

    Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

    Time frame: Multiple dosing: at 2, 5, 8, 12, 25, 45 minutes, 1, 2, 4, 8, 12, 24 hours after the first dose, before Day 5, 6, 7, at 2, 5, 8,1 2, 25, 45 minutes, 1, 2 , 4, 8, 12, 24, 48, 72, 120 hours after Day 7 dose

  19. Accumulation ratio based on peak concentration (Rac (Cmax))

    Accumulation ratio based on peak concentration (Rac (Cmax))

    Time frame: Multiple dosing: at 2, 5, 8, 12, 25, 45 minutes, 1, 2, 4, 8, 12, 24 hours after the first dose, before Day 5, 6, 7, at 2, 5, 8,1 2, 25, 45 minutes, 1, 2 , 4, 8, 12, 24, 48, 72, 120 hours after Day 7 dose

  20. Accumulation ratio based on AUC

    Accumulation ratio based on AUC

    Time frame: Multiple dosing: at 2, 5, 8, 12, 25, 45 minutes, 1, 2, 4, 8, 12, 24 hours after the first dose, before Day 5, 6, 7, at 2, 5, 8,1 2, 25, 45 minutes, 1, 2 , 4, 8, 12, 24, 48, 72, 120 hours after Day 7 dose

07

Study locations

1 site
  • China Japan Friendship Hospital Beijing
    Beijing, Beijing Municipality 100000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Aug 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Dec 5, 2025
StartActual
Nov 25, 2025
Primary completionActual
Aug 21, 2026
CompletionActual
Aug 21, 2026
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07267130
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Nov 25, 2025
Primary completion
Aug 21, 2026
Completion
Aug 21, 2026
Last update
Aug 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion